News

HDA UK Media And Political Bulletin – 9 May 2018

Media and Political Bulletin

9 May 2018

Media Summary

Manufacturers: Generics supply issues sorted but prices still unstable

Chemist and Druggist, Grace Lewis, 8 May 2018

 

Chemist and Druggist reports that generics shortages have “pretty much” been rectified, but prices remain unstable, according to the British Generics Manufacturers Association (BGMA).

Last September, the Pharmaceutical Services Negotiating Committee (PSNC) announced it was in “urgent discussions” with the Department of Health and Social Care (DH) about the “catastrophic” effect of generics shortages on contractors’ cash flow.

Supply issues and price rises were initially triggered by the closure of a Bristol Laboratories manufacturing site in Luton, and a Dr Reddy’s site in India, following inspections by the European Medicines Agency (EMA) the previous month.

Speaking to Chemist and Druggist last month, BGMA director general Warwick Smith said up to 120 products had been affected by the regulatory action.

 

Invest in pharmacists to improve access to medicines, FIP urges

P3 Pharmacy, 8 May 2018

 

P3 Pharmacy highlights the findings of a new report which argues that pharmacists can play a critical role in tackling inefficiencies in the medicines supply chain that leave people in many countries without access to basic life-saving medicines – but that investment is needed to strengthen this aspect of their roles.

The report from the International Pharmaceutical Federation (FIP), Pharmacists in the supply chain: The role of the medicines expert in ensuring quality and availability, looks at the role pharmacists play in safeguarding the supply chain in low-, middle- and high-income countries.

 

 

Parliamentary Coverage

House of Commons – Tabled Written Questions, 8 May 2018

Ian Murray MP: To ask the Secretary of State for Health and Social Care if Brexit meant the UK leaves the European Medicines Agency, whether the Minister could assure the house that would not stop the regulation of new drugs in the UK and stop world class medicine companies from working in the UK.

 

Full Coverage

Manufacturers: Generics supply issues sorted but prices still unstable

Chemist and Druggist, Grace Lewis, 8 May 2018

 

Generics shortages have “pretty much” been rectified, but prices remain unstable, the British Generics Manufacturers Association (BGMA) has told C+D.

Last September, the Pharmaceutical Services Negotiating Committee (PSNC) announced it was in “urgent discussions” with the Department of Health and Social Care (DH) about the “catastrophic” effect of generics shortages on contractors’ cash flow.

Supply issues and price rises were initially triggered by the closure of a Bristol Laboratories manufacturing site in Luton, and a Dr Reddy’s site in India, following inspections by the European Medicines Agency (EMA) the previous month.

Speaking to C+D last month (April 25), BGMA director general Warwick Smith said up to 120 products had been affected by the regulatory action.

PSNC’s list of products on concession show those items that have been most affected since the two suppliers’ licences were suspended and have been subject to higher prices as a result, Mr Smith said.

However, “other manufacturers increased their production to fill the gap” in supply of those affected products, he added.

“My understanding is that there are [now] adequate supplies for all but maybe a couple of products…and the market has pretty much caught up to fill the gap,” he added.

However, the costs involved in increasing production means generics prices may “still be higher” than the prices listed in the DH’s monthly drug tariff, he said.

“There will obviously be a bit of time before prices stabilise,” Mr Smith stressed.

Further price hikes could happen

“We have the lowest prices in Europe and I think we have probably gone as low as we can,” Mr Smith said.

“That means when there are issues to deal with, there is not much wiggle room.”

Mr Smith said while “factors” such as “exchange rates post-Brexit” and the cost of implementing the Falsified Medicines Directive, will not disrupt the supply of generics, “it probably does mean there will be an increase in price”.

“I’m pretty comfortable that manufacturers will meet [demand],” he said, but “if we face that sort of perfect storm” created by these factors, “those prices have to go up”.

These costs will “inevitably” be passed through the supply chain, Mr Smith added.

 

Invest in pharmacists to improve access to medicines, FIP urges

P3 Pharmacy, 8 May 2018

 

A new report argues that pharmacists can play a critical role in tackling inefficiencies in the medicines supply chain that leave people in many countries without access to basic life-saving medicines – but that investment is needed to strengthen this aspect of their roles.

The report from the International Pharmaceutical Federation (FIP), Pharmacists in the supply chain: The role of the medicines expert in ensuring quality and availability, looks at the role pharmacists play in safeguarding the supply chain in low-, middle- and high-income countries.

Ulf Janzon, co-chair of the FIP working group on Pharmacists in the Supply Chain, said: “The report recognises different levels of maturity of supply systems that could be used as a basis for discussion, particularly in developing countries. It doesn’t aim to describe a single gold standard system, but rather, it seeks to highlight that all systems should ensure efficient supply of quality medicines.

”It also draws attention to the effect of globalisation on the supply chain, which is adding complexities to ensuring appropriate quantities of quality medicines.”

In order to help safeguard the global medicines supply chain, pharmacists require training in areas that many degree courses do not cover, the FIP says. Mr Janzon commented that this could include courses in leadership, management and logistics.

HDA UK Media And Political Bulletin – 9 May 2018

From Factory to Pharmacy

As part of our mission to build awareness, understanding and appreciation of the vital importance of the healthcare distribution sector, we developed an infographic explaining the availability of medicines. It identifies the factors that can impact drug supply, as well as the measures that HDA members undertake day in, day out to help mitigate the risks of patients not receiving their medicines.

See the Infographic

Apply to become a Member

Membership of the HDA guarantees your organisation:

  • Access to leading policy and industry forums of debate and discussion
  • Invitations to a range of networking industry events organised through the year, including an Annual Conference and a Business Day
  • Representation on HDA working parties, including the Members’ Liaison Group
  • A daily Political and Media Bulletin and HDA Newsletters
  • Access to HDA policy documents and all sections of the HDA website
  • Branding and marketing opportunities
Apply Now

Already a Member?